ProKidney Corp. (NASDAQ:PROK - Get Free Report) insider Control Empresarial De Capital acquired 1,032,218 shares of the firm's stock in a transaction on Thursday, April 10th. The stock was purchased at an average price of $0.61 per share, for a total transaction of $629,652.98. Following the acquisition, the insider now directly owns 72,592,325 shares in the company, valued at $44,281,318.25. This represents a 1.44 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.
ProKidney Trading Up 1.2 %
NASDAQ:PROK opened at $0.74 on Tuesday. The company has a market cap of $216.60 million, a P/E ratio of -1.35 and a beta of 1.52. ProKidney Corp. has a twelve month low of $0.46 and a twelve month high of $4.44. The company's 50-day moving average price is $1.08 and its 200-day moving average price is $1.53.
ProKidney (NASDAQ:PROK - Get Free Report) last posted its quarterly earnings results on Monday, March 17th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.03). The firm had revenue of $0.08 million during the quarter. On average, analysts expect that ProKidney Corp. will post -0.57 earnings per share for the current year.
Institutional Trading of ProKidney
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. XTX Topco Ltd purchased a new stake in shares of ProKidney in the third quarter valued at about $41,000. ProShare Advisors LLC boosted its holdings in ProKidney by 57.3% in the 4th quarter. ProShare Advisors LLC now owns 30,879 shares of the company's stock valued at $52,000 after purchasing an additional 11,250 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of ProKidney by 54.6% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 37,981 shares of the company's stock valued at $73,000 after buying an additional 13,415 shares during the period. Sei Investments Co. acquired a new stake in shares of ProKidney during the 4th quarter worth approximately $69,000. Finally, JPMorgan Chase & Co. raised its position in shares of ProKidney by 65.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 46,830 shares of the company's stock valued at $90,000 after buying an additional 18,472 shares during the period. 51.59% of the stock is owned by institutional investors and hedge funds.
ProKidney Company Profile
(
Get Free Report)
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
